Ionis’ inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis | News

CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that data from a clinical trial of IONIS-ENAC-2.5Rx demonstrated a significant decrease in the expression of epithelial sodium channel (ENaC) in subjects with cystic fibrosis (CF). The study showed a mean 55.6 percent decrease (p<0.05) in ENaC mRNA expression at the 75 mg dose in the multidose segment of the trial. The study represents the first time an antisense medicine delivered directly to the lung via a nebulizer has shown a significant reduction in ENaC messenger RNA levels. In preclinical studies, ENaC mRNA reductions of 40 percent or more resulted in significant improvement in mouse models of CF lung disease.

IONIS-ENAC-2.5Rx is an investigational antisense medicine designed to reduce the expression of ENaC in the lung. ENaC is believed to be hyperactive in cystic fibrosis, which is caused

Read More

Ionis’ inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis

CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that data from a clinical trial of IONIS-ENAC-2.5Rx demonstrated a significant decrease in the expression of epithelial sodium channel (ENaC) in subjects with cystic fibrosis (CF). The study showed a mean 55.6 percent decrease (p

IONIS-ENAC-2.5Rx is an investigational antisense medicine designed to reduce the expression of ENaC in the lung. ENaC is believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene. Data from the Phase 1 study will be presented via e-poster at the 2020 North American Cystic Fibrosis Conference, which will hold virtual sessions and discussions Oct. 21-23.

Cystic fibrosis is a life-threatening disease affecting approximately 30,000 people in the U.S. and about 70,000 worldwide. Although CF is a multisystem disease, the main cause of

Read More

Takeda Group Begins Manufacturing COVID-19 Plasma Treatment Ahead of Approval | Top News

NEW YORK (Reuters) – The Takeda Pharmaceutical Co-led group that is developing a blood plasma treatment for COVID-19 has started manufacturing while the late-stage trial to determine whether it works is ongoing, Takeda Chief Executive Christophe Weber said on Monday.

The group, known as the CoVIg Plasma Alliance, enrolled its first patient in the Phase III trial on Friday after months of delays. It aims to enroll 500 adult patients from the United States, Mexico and 16 other countries and hope to have results by the end of the year.

“The likelihood it works is very high,” Weber said in an interview. “And that’s why we have launched a campaign in order to accelerate the donation of convalescent plasma to manufacture and produce this product.”

The alliance, which includes CSL Behring, Germany’s Biotest AG and other companies, is testing a hyperimmune globulin therapy, which is derived from blood plasma of

Read More

DNA Dental Comprises the Best Dentist in Dallas, TX, Offering Cosmetic, General, and Restorative Dental Care and Treatment Solutions – Press Release

Dallas, TX – Dallas, TX residents who are in search of 5-star and premium dental care and treatment solutions can now rest assured that the team at DNA Dental brings this quality of services to them at affordable rates. The dental clinic in Dallas, TX boasts a team of experienced and professional dental specialists who are constantly improving on their dental practice to ensure that each patient is given the attention and care they deserve.

Focused on improving the oral health and wellness of the members of the community, DNA Dental has proudly expanded on its dentistry practice to offer a wide range of dental solutions, including the very best children’s dentistry solutions in the area. Children who come into the dental clinic will have access to the very best and experienced pediatric dentists who are committed to creating the best dental care and treatment experiences using the latest dental

Read More

Bill Gates on Trump virus treatment: The word ‘cure’ is inappropriate because it won’t work for everyone

Microsoft founder and philanthropist Bill Gates said Sunday that the monoclonal antibodies treatment President TrumpDonald John TrumpNorth Korea unveils large intercontinental ballistic missile at military parade Trump no longer considered a risk to transmit COVID-19, doctor says New ad from Trump campaign features Fauci MORE received for his coronavirus infection is not a “cure,” but is the most promising option thus far.

“The word ‘cure’ is inappropriate because it won’t work for everyone,” Gates said Sunday on NBC’s “Meet the Press.” “But of all the therapeutics, this is the most promising.”

Gates added that the Bill & Melinda Gates Foundation has “been working with companies doing antibodies, we reserved factory capacity back in the spring, and now we’re partnered with Eli Lilly, who with Regeneron, has been the fastest to get these antibodies ready.”

Read More

Chris Christie released from hospital after treatment for coronavirus

  • Former New Jersey Gov. Chris Christie was released from Morristown Medical Center on Saturday after testing positive for the coronavirus one week ago.
  • “I am happy to let you know that this morning I was released from Morristown Medical Center. I want to thank the extraordinary doctors & nurses who cared for me for the last week,” Christie wrote in a tweet.
  • Christie had been in the hospital for a week and is among several senior Republicans close to President Donald Trump who have contracted the virus.



Chris Christie wearing a suit and tie: Chris Christie, former Governor of New Jersey, center, speaks with attendees following the announcement of U.S. President Donald Trump's nominee for associate justice of the U.S. Supreme Court during a ceremony in the Rose Garden of the White House in Washington, D.C., on Saturday, Sept. 26, 2020.


© Provided by CNBC
Chris Christie, former Governor of New Jersey, center, speaks with attendees following the announcement of U.S. President Donald Trump’s nominee for associate justice of the U.S. Supreme Court during a ceremony in the Rose Garden of the White House in Washington, D.C., on Saturday, Sept. 26, 2020.

Former New Jersey Gov. Chris Christie was released from Morristown Medical Center 

Read More

Chris Christie released from hospital after receiving treatment for COVID-19

Chris Christie was released from a New Jersey hospital on Saturday, a week after he was admitted following a positive COVID-19 test. Christie, who made the announcement on Twitter, has been quiet on social media since he began treatment last weekend.

“I am happy to let you know that this morning I was released from Morristown Medical Center,” Christie tweeted Saturday. “I want to thank the extraordinary doctors & nurses who cared for me for the last week. Thanks to my family & friends for their prayers. I will have more to say about all of this next week.”

Read More

Trump sparks new FDA concerns with praise of ‘miracle’ treatment

President Trump’s public praise for an experimental coronavirus antibody treatment is putting new pressure on the Food and Drug Administration (FDA) to quickly give emergency clearance to a drug he has touted as a “miracle.”



a person sitting on a table: Trump sparks new FDA concerns with praise of 'miracle' treatment


© Getty Images
Trump sparks new FDA concerns with praise of ‘miracle’ treatment

Doctors think the drugs show promise as a potential treatment of COVID-19, though Trump has created confusion by quickly elevating them to a cure.

Loading...

Load Error

“They call them therapeutic, but to me it wasn’t therapeutic,” Trump said in a video he tweeted on Wednesday, five days after receiving the experimental treatment from the biotech company Regeneron.

Trump said that he felt better immediately after taking the drugs.

“I call that a cure,” he said. “It’s a cure.”

But by placing himself in the middle of the drug evaluation process, Trump is once again igniting concerns that politics is encroaching on science

Read More

U.S. signs agreement with AstraZeneca to develop, supply COVID-19 antibody treatment

(Reuters) – The U.S. government on Friday signed an agreement with AstraZeneca Plc <AZN.L> worth $486 million to develop and secure supplies of up to 100,000 doses of COVID-19 antibody treatment, a similar class of drugs that was used to treat President Donald Trump.

The U.S. health agency will provide the funding to AstraZeneca for two Phase 3 clinical trials under operation Warp Speed, which is aimed at speeding up treatments and vaccines for COVID-19.

One trial will evaluate the safety and efficacy of the experimental treatment to prevent infection for up to 12 months, in about 5,000 participants, while the second trial will evaluate post-exposure preventative and pre-emptive treatment in roughly 1,100 participants.

AstraZeneca said it plans to supply up to 100,000 doses starting towards the end of 2020 and the US Government can acquire up to an additional one million doses in 2021 under a separate agreement.

In

Read More

U.S. Signs Agreement With AstraZeneca to Develop, Supply COVID-19 Antibody Treatment | Top News

(Reuters) – The U.S. government on Friday signed an agreement with AstraZeneca Plc

worth $486 million to develop and secure supplies of up to 100,000 doses of COVID-19 antibody treatment, a similar class of drugs that was used to treat President Donald Trump.

The U.S. health agency will provide the funding to AstraZeneca for two Phase 3 clinical trials under operation Warp Speed, which is aimed at speeding up treatments and vaccines for COVID-19.

One trial will evaluate the safety and efficacy of the experimental treatment to prevent infection for up to 12 months, in about 5,000 participants, while the second trial will evaluate post-exposure preventative and pre-emptive treatment in roughly 1,100 participants.

AstraZeneca said it plans to supply up to 100,000 doses starting towards the end of 2020 and the US Government can acquire up to an additional one million doses in 2021 under a separate agreement.

In a

Read More